Cargando…
CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients
Autores principales: | Cassinat, Bruno, Verger, Emmanuelle, Maslah, Nabih, Gauthier, Nicolas, Vainchenker, William, Giraudier, Stéphane, Kiladjian, Jean-Jacques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927990/ https://www.ncbi.nlm.nih.gov/pubmed/32414847 http://dx.doi.org/10.3324/haematol.2020.252643 |
Ejemplares similares
-
Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape
por: Maslah, Nabih, et al.
Publicado: (2023) -
JAK2(V617F) myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML
por: Dagher, Tracy, et al.
Publicado: (2020) -
Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022) -
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
por: Verger, Emmanuelle, et al.
Publicado: (2018) -
Molecular approach to diagnose BCR/ABL negative chronic myeloproliferative neoplasms
por: Barcelos, Michelle Maccarini, et al.
Publicado: (2011)